Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Leukemia

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 26 articles:
HTML format
Text format



Single Articles


    July 2019
  1. HUANG S, Pan J, Jin J, Li C, et al
    Abivertinib, a novel BTK inhibitor: anti-leukemia effects and synergistic efficacy with Homoharringtonine in acute myeloid leukemia.
    Cancer Lett. 2019 Jul 13. pii: S0304-3835(19)30404.
    PubMed     Text format     Abstract available


  2. YANG Q, Chen K, Zhang L, Feng L, et al
    Synthetic Lethality of Combined AT-101 with Idarubicin in Acute Myeloid Leukemia via Blockade of DNA Repair and Activation of Intrinsic Apoptotic Pathway.
    Cancer Lett. 2019 Jul 10. pii: S0304-3835(19)30399.
    PubMed     Text format     Abstract available


    June 2019
  3. GAZI M, Moharram SA, Marhall A, Kazi JU, et al
    Corrigendum to "The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)" [Cancer Lett. 392 (1) (2017) 9-16].
    Cancer Lett. 2019 Jun 4. pii: S0304-3835(19)30301.
    PubMed     Text format    


    April 2019
  4. NUNES RODRIGUES ALVES AP, Fernandes JC, Fenerich BA, Coelho-Silva JL, et al
    IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells.
    Cancer Lett. 2019 Apr 28. pii: S0304-3835(19)30267.
    PubMed     Text format     Abstract available


  5. DELLOMO AJ, Baer MR, Rassool FV
    Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD.
    Cancer Lett. 2019 Apr 3. pii: S0304-3835(19)30212.
    PubMed     Text format     Abstract available


    March 2019
  6. PETRICK LM, Schiffman C, Edmands WMB, Yano Y, et al
    Metabolomics of Neonatal Blood Spots Reveal Distinct Phenotypes of Pediatric Acute Lymphoblastic Leukemia and Potential Effects of Early-life Nutrition.
    Cancer Lett. 2019 Mar 20. pii: S0304-3835(19)30163.
    PubMed     Text format     Abstract available


    December 2018
  7. TANG YL, Sun X, Huang LB, Liu XJ, et al
    Melatonin inhibits MLL-rearranged leukemia via RBFOX3/hTERT and NF-kappaB/COX-2 signaling pathways.
    Cancer Lett. 2018 Dec 10. pii: S0304-3835(18)30703.
    PubMed     Text format     Abstract available


    October 2018
  8. ZHANG JM, Wang CC, Zhang GC, Jiang Q, et al
    ADAM28 promotes tumor growth and dissemination of acute myeloid leukemia through IGFBP-3 degradation and IGF-I-induced cell proliferation.
    Cancer Lett. 2018;442:193-201.
    PubMed     Text format     Abstract available


    September 2018
  9. WANG Y, Chen H, Chen J, Han M, et al
    The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China.
    Cancer Lett. 2018;438:63-75.
    PubMed     Text format     Abstract available


    June 2018
  10. LEE YC, Wang LJ, Huang CH, Shi YJ, et al
    ABT-263-induced MCL1 upregulation depends on autophagy-mediated 4EBP1 downregulation in human leukemia cells.
    Cancer Lett. 2018 Jun 15. pii: S0304-3835(18)30417.
    PubMed     Text format     Abstract available


    May 2018
  11. ZHANG X, Zheng X, Yang H, Yan J, et al
    Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis.
    Cancer Lett. 2018 May 29. pii: S0304-3835(18)30367.
    PubMed     Text format     Abstract available


    April 2018
  12. ZHU L, Liu X, Pu W, Peng Y, et al
    tRNA-derived small non-coding RNAs in human disease.
    Cancer Lett. 2018;419:1-7.
    PubMed     Text format     Abstract available


  13. RYU S, Kim DS, Lee MW, Lee JW, et al
    Anti-leukemic effects of PPARgamma ligands.
    Cancer Lett. 2018;418:10-19.
    PubMed     Text format     Abstract available


    March 2018
  14. HU X, Mei S, Meng W, Xue S, et al
    CXCR4-mediated signaling regulates autophagy and influences acute myeloid leukemia cell survival and drug resistance.
    Cancer Lett. 2018 Mar 21. pii: S0304-3835(18)30221.
    PubMed     Text format     Abstract available


  15. FARAONI I, Aloisio F, De Gabrieli A, Consalvo MI, et al
    The poly(adp-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by nf-kappab activation.
    Cancer Lett. 2018 Mar 8. pii: S0304-3835(18)30197.
    PubMed     Text format     Abstract available


    February 2018
  16. VELA M, Corral D, Carrasco P, Fernandez L, et al
    Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia.
    Cancer Lett. 2018 Feb 22. pii: S0304-3835(18)30172.
    PubMed     Text format     Abstract available


  17. HE Y, Sun L, Xu Y, Fu L, et al
    Combined inhibition of PI3Kdelta and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia.
    Cancer Lett. 2018;420:49-59.
    PubMed     Text format     Abstract available


  18. TORELLO CO, Shiraishi RN, Della Via FI, Castro TCL, et al
    Reactive oxygen species production triggers green tea-induced anti-leukaemic effects on acute promyelocytic leukaemia model.
    Cancer Lett. 2018;414:116-126.
    PubMed     Text format     Abstract available


    January 2018
  19. DE COLA A, Franceschini M, Di Matteo A, Colotti G, et al
    N6L pseudopeptide interferes with nucleophosmin protein-protein interactions and sensitizes leukemic cells to chemotherapy.
    Cancer Lett. 2018;412:272-282.
    PubMed     Text format     Abstract available


    October 2017
  20. WEN S, Wang J, Liu P, Li Y, et al
    Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
    Cancer Lett. 2017 Oct 22. pii: S0304-3835(17)30650.
    PubMed     Text format     Abstract available


    September 2017
  21. COLLADO R, Puiggros A, Lopez-Guerrero JA, Calasanz MJ, et al
    Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes.
    Cancer Lett. 2017 Sep 6. pii: S0304-3835(17)30536.
    PubMed     Text format     Abstract available


  22. SADRAS T, Heatley SL, Kok CH, Dang P, et al
    Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.
    Cancer Lett. 2017 Sep 1. pii: S0304-3835(17)30521.
    PubMed     Text format     Abstract available


    August 2017
  23. PRIGOZHINA TB, Szafer F, Aronin A, Tzdaka K, et al
    Fn14.TRAIL fusion protein is oligomerized by TWEAK into a superefficient TRAIL analog.
    Cancer Lett. 2017;400:99-109.
    PubMed     Text format     Abstract available


    July 2017
  24. MOHARRAM SA, Shah K, Khanum F, Marhall A, et al
    Efficacy of CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia.
    Cancer Lett. 2017 Jul 26. pii: S0304-3835(17)30455.
    PubMed     Text format     Abstract available


    April 2017
  25. ESPINOZA JL, Elbadry MI, Taniwaki M, Harada K, et al
    The simultaneous inhibition of the mTOR and MAPK pathways with Gnetin-C induces apoptosis in acute myeloid leukemia.
    Cancer Lett. 2017 Apr 26. pii: S0304-3835(17)30288.
    PubMed     Text format     Abstract available


    February 2017
  26. PIAO J, Takai S, Kamiya T, Inukai T, et al
    Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
    Cancer Lett. 2017;386:131-140.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: